Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Earnings for Roivant Sciences Ltd. (ROIV)
Earnings in 2024 (TTM): $4.25 B
According to Roivant Sciences Ltd.'s latest financial reports the company's current earnings (TTM) are $4.25 B. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Roivant Sciences Ltd.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $4.25 B | $4.35 B |
| 2023 | $-1,224,834,000 | $-1,230,024,000 |
| 2022 | $-923,747,000 | $-924,116,000 |
| 2021 | $-898,547,000 | $-900,233,000 |
| 2020 | $-560,986,000 | $1.2 B |
| 2019 | $-807,182,000 | $-1,041,969,000 |